• Corpus ID: 438704

The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects.

@article{Carlson2007ThePP,
  title={The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects.},
  author={David A. Carlson and Anthony R. W. Smith and Sarah J. Fischer and Karyn L. Young and Lester Packer},
  journal={Alternative medicine review : a journal of clinical therapeutic},
  year={2007},
  volume={12 4},
  pages={
          343-51
        }
}
BACKGROUND The racemic mixture, RS-(+/-)-alpha-lipoic acid (rac-LA) has been utilized clinically and in a variety of disease models. Rac-LA and the natural form, R-lipoic acid (RLA), are widely available as nutritional supplements, marketed as antioxidants. Rac-LA sodium salt (NaLA) or rac-LA potassium salt (KLA) has been used to improve the aqueous solubility of LA. STUDY RATIONALE Several in vitro and animal models of aging and age-related diseases have demonstrated efficacy for the oral… 

Figures and Tables from this paper

Bioavailability of an R-α-Lipoic Acid/γ-Cyclodextrin Complex in Healthy Volunteers

Results indicate that R-LA/CD could be easily absorbed in the intestine, and γ-CD complexation is a promising technology for delivering functional but unstable ingredients like R- LA.

Single dose bioavailability and pharmacokinetic study of a innovative formulation of α-lipoic acid (ALA600) in healthy volunteers.

AlA600 formulation is characterized by rapid absorption, high bioavailability, brief half-life and low toxicity, and might also prove to be the most suitable formulation for chronic administration such as peripheral neuropathies.

(R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy.

In animal models, R-ALA in a liquid formulation amplifies the recovery of the conduction velocity of sensory and motor nerves altered by diabetic neuropathy, suggesting a new therapeutic scenario for numerous oxidative stress-dependent pathologies requiring chronic treatment.

Pharmacokinetics of orally administered DL-α-lipoic acid in dogs.

Values for pharmacokinetic parameters of orally administered DL-α-lipoic acid may differ significantly when there are changes in dosage, method of administration, and fed status.

Alpha-Lipoic Acid as a Nutritive Supplement for Humans and Animals: An Overview of Its Use in Dog Food

The utility of alpha-lipoic acid has utility as a nutritive additive at concentrations of 2.7–4.94 mg/kg body weight/day and improves antioxidant capacity in dogs.

Evaluation of Dissolution Profiles of a Newly Developed Solid Oral Immediate-Release Formula Containing Alpha-Lipoic Acid

It is essential to ensure a formulation with an in vitro dissolution comparable with the RLD, allowing the compound to reach its target level to assure the optimum claimed antioxidant activity of ALA at the cellular level, even for food supplement formulations.

R-enantiomer of α-lipoic acid. Opportunities and prospects for clinical use

An analysis of current literature data on the use of the R-enantiomer of α-lipoic acid as an antihypertensive treatment in patients with hypertension and metabolic syndrome finds that it had strong antioxidant effects, and its dose of 300 mg is bioequivalent to 600 mg of racemic α- Lipoic Acid.

Comparison of R(+)-α-lipoic acid exposure after R(+)-α-lipoic acid 200 mg and 300 mg and thioctic acid 600 mg in healthy Korean male subjects

R(+)-α-lipoic acid 300 mg showed PK characteristics similar to those of thioctic acid 600 mg and both formulations were well tolerated.

Evaluation of Dissolution Profiles of a Newly Developed Solid Oral Immediate-Release Formula Containing Alpha-Lipoic Acid

It is essential to ensure a formulation with an in vitro dissolution comparable with the RLD, allowing the compound to reach its target level to assure the optimum claimed antioxidant activity of ALA at the cellular level, even for food supplement formulations.
...

References

SHOWING 1-10 OF 65 REFERENCES

Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha‐Lipoic Acid following Oral Administration in Healthy Volunteers

The results of the present study revealed that urinary excretion of alpha‐lipoic acid and five of its main metabolites does not play a significant role in the elimination ofalpha‐lipOic acid, and biliary excretion, further electrochemically inactive degradation products, and complete utilization of alpha-lipoIC acid as a primary substrate in the endogenous metabolism should be considered.

Dose-proportionality of oral thioctic acid--coincidence of assessments via pooled plasma and individual data.

Effect of R(+)alpha-lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes.

3-hour exposure of primary cultured rat hepatocytes to R-LA at therapeutically relevant concentrations increased pyruvate oxidation, apparently by activation of the PDH complex, and decreased gluconeogenesis and FFA oxidation, which may prove useful in the control of type 2 diabetes.

Absorption of [7,8-14C]rac-a-lipoic acid from in situ ligated segments of the gastrointestinal tract of the rat.

High and nearly complete absorption was investigated in the rat after oral administration and the question was investigated if the absorption is restricted to only a small area of the GI tract or is extended over a wider area, which is expected to make the absorption less sensitive against variations caused by gastrointestinal disturbances due to longer residence times in theGI tract.

Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle.

Chronic parenteral treatment with the antioxidant ALA enhances insulin-stimulated glucose transport and non-oxidative and oxidative glucose metabolism in insulin-resistant rat skeletal muscle, with the R-(+) enantiomer being much more effective than the S-(-) enantiomers.

Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.

CRLA increased the plasma concentration of LA over time in healthy subjects, and CRLA was safe, well tolerated, and effective in reducing plasma fructosamine in patients with type 2 diabetes.
...